Summary
Purpose We evaluated the safety and efficacy of intetumumab in combination with docetaxel in patients with castrate-resistant metastatic prostate cancer. Patients and methods In this phase 1, open-label, multicenter, nonrandomized study, 75 mg/m2 docetaxel was administered on Day 1 of each of nine 21-day treatment cycles and intetumumab 5 or 10 mg/kg was administered on Days 1, 8, and 15 of Cycles 2 and 3 and on Day 1 of all subsequent cycles. The primary endpoint was the incidence of dose-limiting toxicities (DLTs) during Cycles 2 and 3. Secondary endpoints included serum prostate-specific antigen (PSA) response and objective response based on Response Evaluation Criteria in Solid Tumors (RECIST). Results Ten patients were treated (5 mg/kg n = 3, 10 mg/kg n = 7). No DLTs occurred. Most treatment-emergent adverse events (TEAEs) occurred in the 10-mg/kg intetumumab group. Common TEAEs were neutropenia (10 mg/kg n = 6) and nausea (5 mg/kg n = 1, 10 mg/kg n = 5). Four 10-mg/kg-treated patients reported serious TEAEs; of these, only febrile neutropenia was considered probably intetumumab-related. In the 10-mg/kg group, four patients had a serum PSA response (two of whom responded within 3 months of treatment), one patient demonstrated partial tumor response for 11 weeks, and none had progressive disease at Cycle 9. No PSA or tumor response was observed in the 5-mg/kg group. Conclusions Intetumumab was generally safe and well tolerated in combination with docetaxel, with a higher incidence of TEAEs in the 10 mg/kg dose cohort. The efficacy of 10 mg/kg intetumumab in combination with docetaxel appears to warrant further study.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96
Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253–8261
Rubin MA, Putzi M, Mucci N et al (2000) Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 6:1038–1045
Scher HI, Chung LW (1994) Bone metastases: improving the therapeutic index. Semin Oncol 21:630–656
Sternberg CN (2001) Systemic treatment and new developments in advanced prostate cancer. Eur J Cancer 37(Suppl 7):S147–S157
Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582–1584
Folkman J (1995) Tumor angiogenesis. In: Mendelsohn J, Howley PM, Isreal MA, Liotta LA (eds) The molecular basis of cancer. W.B. Saunders, Philadelphia, pp 206–232
Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571
Brooks PC, Montgomery AM, Rosenfeld M et al (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164
Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–1822
Bisanz K, Yu J, Edlund M et al (2005) Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 12:634–643
Cooper CR, Chay CH, Pienta KJ (2002) The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 4:191–194
De S, Chen J, Narizhneva NV et al (2003) Molecular pathway for cancer metastasis to bone. J Biol Chem 278:39044–39050
Edlund M, Miyamoto T, Sikes RA et al (2001) Integrin expression and usage by prostate cancer cell lines on laminin substrata. Cell Growth Differ 12:99–107
Lecrone V, Li W, Devoll RE, Logothetis C, Farach-Carson MC (2000) Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium 27:35–42
Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR (1999) Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59:1655–1664
Sanofi-Aventis U.S.: Taxotere Prescribing Information. Available at http://products.sanofi-aventis.us/Taxotere/taxotere.html. Revised November 2008.
Mullamitha SA, Ton NC, Parker GJ et al (2007) Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13:2128–2135
Shaffer DR, Leversha MA, Danila DC et al (2007) Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13:2023–2029
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
Willett CG, Duda DG, di Tomaso E et al (2009) Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 27:3020–3026
Acknowledgments
The authors thank the following investigators and site personnel for their participation in this study: F.M. Chu, D.J. Lama, S. Kim of San Bernardino Urological Associates Medical Group, San Bernardino CA; P.M. Fracasso, J. Picus, P. Hruska, K.A. Bergeron, A.N. Creekmore, S.L. Myles of Siteman Cancer Center at Washington University School of Medicine, St. Louis MO; R. Dreicer, A. Al-Hazzour, S. Black, J. Bray, J. Garcia, T. Filligan, V. Lipnickey, T. Rich, D. Raghavan, B. Rini, I. Tamaskar of The Cleveland Clinic, Cleveland OH.
The authors thank Jennifer Han and Robert Achenbach of Centocor Ortho Biotech Inc. for assistance in drafting, revising, and preparing the manuscript.
Financial support for this study was provided by Centocor, Inc., Malvern, PA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chu, F.M., Picus, J., Fracasso, P.M. et al. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs 29, 674–679 (2011). https://doi.org/10.1007/s10637-010-9388-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-010-9388-4